ARS Pharmaceuticals, Inc. — Director's Dealing 2024

Aug 22, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2024-08-19

Reporting Person: Karas Eric (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-08-19	Common Stock	M	10000	$1.50	Acquired	15693	Direct
2024-08-19	Common Stock	S	10000	$14	Disposed	5693	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-08-19	Stock Option (Right to Buy)	$1.50	M	10000	Disposed	2032-05-23	Common Stock (10000)	Direct

Footnotes

F1: Includes 1,984 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") on June 30, 2023, 1,232 shares acquired under the ESPP on December 29, 2023 and 2,477 shares acquired under the ESPP on June 28, 2024.

F2: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024.

F3: Immediately exercisable.